
Image Credit: Mindtrix
Chinese implantable neurotechnology developer Mindtrix has completed pre-A and pre-A+ financing rounds, bringing its reported cumulative funding above RMB 500 million. The proceeds are intended to support engineering of a 1,024-channel visual-reconstruction system, preparation for product and registration testing, and multicenter clinical research.
Mindtrix describes an approach that converts external images into electrical stimulation of the visual cortex, bypassing damaged eyes and optic nerves. Its development platform includes recording and stimulation electrodes, wireless power and data transfer, and closed-loop control.









Second Sight Medical Products, Inc., located in Los Angeles, CA, was founded in 1998 by Alfred Mann to develop a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations, such as Retinitis Pigmentosa.
Alfred E. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel), as well as, Research Professor, University of Southern California, and Adjunct Professor, Dept. of Bioengineering, University of California Los Angeles.